Venous thrombosis: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett mNo edit summary |
imported>Robert Badgett (Started treatment) |
||
| Line 4: | Line 4: | ||
Superficial venous thrombosis can be associated with [[deep venous thrombosis]] and an accompanying deep venous thrombosis occurring simultaneously or later.<ref name="pmid20157136">{{cite journal| author=Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M et al.| title=Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 4 | pages= 218-24 | pmid=20157136 | Superficial venous thrombosis can be associated with [[deep venous thrombosis]] and an accompanying deep venous thrombosis occurring simultaneously or later.<ref name="pmid20157136">{{cite journal| author=Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M et al.| title=Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 4 | pages= 218-24 | pmid=20157136 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20157136 | doi=10.1059/0003-4819-152-4-201002160-00006 }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20157136 | doi=10.1059/0003-4819-152-4-201002160-00006 }} </ref> | ||
==Treatment== | |||
"Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects" according to a [[randomized controlled trial]]. <ref name="pmid20860504">{{cite journal| author=Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B et al.| title=Fondaparinux for the treatment of superficial-vein thrombosis in the legs. | journal=N Engl J Med | year= 2010 | volume= 363 | issue= 13 | pages= 1222-32 | pmid=20860504 | doi=10.1056/NEJMoa0912072 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 07:04, 29 September 2010
In medicine, superficial venous thrombosis is a form of embolism and thrombosis.
Prognosis
Superficial venous thrombosis can be associated with deep venous thrombosis and an accompanying deep venous thrombosis occurring simultaneously or later.[1]
Treatment
"Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects" according to a randomized controlled trial. [2]
References
- ↑ Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M et al. (2010). "Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study.". Ann Intern Med 152 (4): 218-24. DOI:10.1059/0003-4819-152-4-201002160-00006. PMID 20157136. Research Blogging.
- ↑ Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B et al. (2010). "Fondaparinux for the treatment of superficial-vein thrombosis in the legs.". N Engl J Med 363 (13): 1222-32. DOI:10.1056/NEJMoa0912072. PMID 20860504. Research Blogging.